Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
4
50%
Ph phase_3
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

completed675%
terminated225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00097851
completedphase_2

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00103389
completedphase_1

Study of PI-88 in Patients With Advanced Melanoma

NCT00068172
completedphase_1

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

NCT00073892
completedphase_2

PI-88 in Hepatocellular Carcinoma After Hepatectomy

NCT00247728
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00097851Phase 2

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Completed
NCT00103389Phase 2

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed
NCT00068172Phase 1

Study of PI-88 in Patients With Advanced Melanoma

Completed
NCT00073892Phase 1

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Completed
NCT00247728Phase 2

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Completed
NCT01402908Phase 3

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

Terminated
NCT00568308Phase 3

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Terminated
NCT00268593Phase 2

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8